InnoCare Initiates Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis Treatment
核心洞察
InnoCare Pharma (搜索) has dosed the first patient in a global Phase II clinical trial of Soficitinib (搜索) (ICP-332), a novel TYK2 (搜索) inhibitor, for treating prurigo nodularis (搜索) in China.
Soficitinib (搜索) targets the JAK-STAT signaling pathway by blocking cytokines IL-4 (搜索), IL-13 (搜索), and IL-31 (搜索) to reduce neurogenic itch responses and skin inflammation in this chronic condition.
The global prurigo nodularis (搜索) market, affecting approximately 10 million patients worldwide, is valued at $2 billion in 2024 and projected to reach $3 billion by 2034.
InnoCare Pharma (搜索) has achieved a significant milestone in its dermatology pipeline with the dosing of the first patient in a global Phase II clinical trial of Soficitinib (搜索) (ICP-332) for prurigo nodularis (搜索) treatment in China. The Beijing-based biopharmaceutical company announced this development as part of its expanding focus on autoimmune dermatological conditions.
Novel TYK2 Inhibition Mechanism
Soficitinib (搜索) represents a potent and selective TYK2 (搜索) inhibitor designed to treat various T-cell related autoimmune disorders. The drug targets TYK2, which plays a key role in the JAK-STAT signaling pathway and is critical in the pathogenesis of inflammatory diseases. By blocking the signaling pathways of cytokines related to itching and inflammation, including IL-4 (搜索), IL-13 (搜索), and IL-31 (搜索), Soficitinib aims to reduce neurogenic itch responses and inhibit skin inflammation.
Addressing Significant Unmet Medical Need
Prurigo nodularis (搜索) presents as a chronic inflammatory skin disease characterized by severe itching and skin nodules, which significantly impairs patients' quality of life. The condition affects approximately 10 million patients worldwide, representing a substantial patient population with limited treatment options.
The global prurigo nodularis (搜索) market demonstrates considerable commercial potential, valued at $2 billion in 2024 and expected to grow to $3 billion by 2034, according to Global Market Insights data.
Expanding Dermatology Portfolio
InnoCare's strategic positioning within the dermatology market encompasses multiple indications under development, including atopic dermatitis (搜索), vitiligo (搜索), prurigo nodularis (搜索), and urticaria (搜索). The company's pipeline now covers ten major autoimmune diseases with particular emphasis on dermatological conditions.
Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, emphasized the company's commitment to dermatology development: "InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions. The Phase II clinical study of Soficitinib (搜索) for moderate-to-severe atopic dermatitis (搜索) demonstrated outstanding efficacy and a strong safety profile."
Previous Clinical Success
The company has already demonstrated Soficitinib (搜索)'s therapeutic potential in related dermatological conditions. Phase II clinical data for moderate-to-severe atopic dermatitis (搜索) showed outstanding efficacy and a strong safety profile. These results were presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting, highlighting the scientific community's recognition of the drug's potential.
Global Development Strategy
InnoCare is accelerating global clinical development to bring innovative therapies to autoimmune patients worldwide. The company operates as a commercial-stage biopharmaceutical organization committed to discovering, developing, and commercializing first-in-class and best-in-class drugs for cancers and autoimmune diseases with unmet medical needs in China and globally.
With branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States, InnoCare maintains a comprehensive global presence to support its expanding clinical development programs across multiple therapeutic areas.